Clear clinical remission of a diffuse metastasized ovarian clear cell carcinoma with third line chemotherapy

References

• Crozier M A, Copeland L J, Silva E G, Gershenson D M, Stringer C A. Clear cell adenocarcinoma of the ovary: a study of 59 cases. Gynecol Oncol 1989; 35: 199–203
   PubMed Web of Science ®Google Scholar
• Kennedy A W, Biscotti C V, Hart W R, Webster K D. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989; 32: 342–9
   PubMedGoogle Scholar
• Jenison E L, Montag A G, Griffiths C T, Welch W R, Lavin P T, Greer J, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989; 32: 65–71
   PubMed Web of Science ®Google Scholar
• Vander Burg M E, Lammes F B, Verweij J. Ca 125 in ovarian cancer. A review. Neth J Med 1992; 40: 36–51
   Google Scholar
• Rustin G J, Nelstrop A K, McClean P, Brady M F, MacGuire W P, Hoskins W J, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum Ca 125. J Clin Oncol 1996; 14: 1545–51
   PubMed Web of Science ®Google Scholar
• Seymour M T, Mansi J L, Gallagher C J, Gore M E, Harper P G, Evans T R, et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. Br J Cancer 1994; 69: 191–5
   PubMed Web of Science ®Google Scholar
• O'Brien M E, Schofield J B, Tan S, Fryatt I, Fisher C, Wiltshaw E. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993; 49: 250–4
   Google Scholar
• Goff B A, Sainz dela Cuesta R, Muntz H G, Fleischmacker D, Ek M, Rice L W, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996; 60: 412–7
   PubMed Web of Science ®Google Scholar
• Eiermann W, Achterrath W, Lenaz L, Hepp H. Carboplat in/etoposide as first-line chemo-therapy in advanced ovarian carcinoma: a pilot study. Cancer Chemother Pharmacol 1991; 27: 389–93
   PubMed Web of Science ®Google Scholar
• Hoskins P J, Swenerton K D. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994; 12: 60–3
   PubMed Web of Science ®Google Scholar
• De Jong R S, Mulder N H, Dijksterhuis D, De Vries E G. Review of clinical experience with prolonged (oral) etoposide. Anticancer Res 1995; 15: 2319–30
   PubMed Web of Science ®Google Scholar
• Myers A M, Moore G E, Major F J. Advanced ovarian carcinoma: response to antiestrogen therapy. Cancer 1981; 48: 2368–70
   PubMed Web of Science ®Google Scholar
• Slotman B J, Rao B R. Ovarian cancer: a review. Anticancer Res 1988; 8: 417–34
   PubMed Web of Science ®Google Scholar
• De Palo G. Staging and treatment of ovarian carcinoma. Acta Oncol 1989; 28: 163–76
   Google Scholar
• Vander Vange N, Greggi S, Burger C W, Kenemans P, Vermorken J B. Experience with hormonal therapy in advanced epithelial ovarian cancer. Acta Oncol 1995; 34: 813–20
   Google Scholar
• Hatch K D, Beecham J B, Biessing J A, Creasman W T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. Cancer 1991; 68: 269–71
   PubMed Web of Science ®Google Scholar
• Hillcoat B L, Campbell J J, Pepperell R, Quin M A, Bishop J F, Day A. Phase II trial of VP-16–213 in advanced ovarian carcinoma. Gynecol Oncol 1985; 22: 162–6
   Google Scholar
• Wakisaka T, Sou S. A case of recurrent ovarian cancer successfully treated with etoposide. Jpn J Cancer Chemother 1988; 15: 1795–8
   Google Scholar
• Hansen F, Malthe I, Krog H. Phase II clinical trial of VP-16–213 (etoposide) administered orally in advanced ovarian carcinoma. Gynecol Oncol 1990; 36: 369–70
   Google Scholar
• Takeda S, Takada S, Kojima T, Kinoshita K, Sakamoto S. Oral etoposide therapy in stage III-IV ovarian carcinoma. J Jpn Soc Cancer Ther 1990; 25: 2562–6
   Google Scholar
• Takeda S, Takada S, Kojima T, Kinoshita K, Sakamoto S. A case of stage III ovarian carcinoma successfully treated with oral etoposide. Jpn J Cancer Chemother 1990; 17: 1929–31
   Google Scholar
• Fujita H, Ito R, Yamamoto T, Okada H. A case of recurrent ovarian cancer markedly responding to daily oral administration of low dose etoposide. Jpn J Cancer Chemother 1990; 17: 2261–4
   Google Scholar
• Eckhardt S, Hernadi Z, Thurzo L. Phase II clinical evaluation of etoposide (VP-16213, vepesid) as a second-line treatment in ovarian cancer. Oncology 1990; 47: 289–95
   Google Scholar
• Markman M, Hakes T, Reichman B, Curtin J, Barakat R, Rubin S, et al. Phase II trial of chronic low-dose oral etoposide as salvage therapy of platinum refractory ovarian cancer. J Cancer Res Clin Oncol 1992; 119: 55–7
   PubMed Web of Science ®Google Scholar
• Marzola M, Zucchetti M, Colombo N, Sessa C, Pagani O, D'lncalci M, et al. Low dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 1993; 4: 517–9
   Google Scholar
• Marth C, Poitner A G, Zeimet A G, Abfalter E, Koza A, Windbichler G, et al. Die Wertigkeit von Etoposid (VP-16) in der Therapie des refractären Ovarialkarzinoms. (Value of etoposid (VP-16) for the treatment of refractory ovarian carcinoma). Geburtshilf Frauenheilkd 1993; 53: 303–7
   Google Scholar
• De Wit R, Vander Burg M E, Van der Gaast A, Logmans A, Stoter G, Verwey J. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. Ann Oncol 1994; 5: 656–7
   PubMed Web of Science ®Google Scholar
• Kuhn W, Schmalfeldt B, Dose J, Pache L, Ulm K, Freitag K, et al. Die intravenöse oder orale Etoposid-Therapie des Platin-refraktären Ovarialkarzinom-Früh-rezidivs. (Intravenoous or oral Etoposid for ovarian carcinoma refractory to Platinol). Geburtshilf Frauenheilkd 1996; 56: 105–10
   Google Scholar